Forte Biosciences Statistics
Share Statistics
Forte Biosciences has 1.46M shares outstanding. The number of shares has increased by -95.98% in one year.
| Shares Outstanding | 1.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -95.99% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.28M |
| Failed to Deliver (FTD) Shares | 83 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 982, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 982 |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 0.09 |
Valuation Ratios
The PE ratio is -0.82 and the forward PE ratio is -0.31.
| PE Ratio | -0.82 |
| Forward PE | -0.31 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.73 |
| P/FCF Ratio | -0.9 |
| PEG Ratio | n/a |
Enterprise Valuation
Forte Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 10.45, with a Debt / Equity ratio of 0.
| Current Ratio | 10.45 |
| Quick Ratio | 10.45 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.89% and return on capital (ROIC) is -91.99%.
| Return on Equity (ROE) | -0.89% |
| Return on Assets (ROA) | -0.81% |
| Return on Capital (ROIC) | -91.99% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.86M |
| Employee Count | 11 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 25.44% in the last 52 weeks. The beta is 1.46, so Forte Biosciences 's price volatility has been higher than the market average.
| Beta | 1.46 |
| 52-Week Price Change | 25.44% |
| 50-Day Moving Average | 10.47 |
| 200-Day Moving Average | 12.81 |
| Relative Strength Index (RSI) | 67.88 |
| Average Volume (20 Days) | 538.99K |
Income Statement
In the last 12 months, Forte Biosciences had revenue of $0 and earned -$31.48M in profits. Earnings per share was $-24.92.
| Revenue | 0 |
| Gross Profit | -9.00K |
| Operating Income | -32.49M |
| Net Income | -31.48M |
| EBITDA | -32.48M |
| EBIT | - |
| Earnings Per Share (EPS) | -24.92 |
Balance Sheet
The company has $11.96M in cash and $0 in debt, giving a net cash position of $11.96M.
| Cash & Cash Equivalents | 11.96M |
| Total Debt | 0 |
| Net Cash | 11.96M |
| Retained Earnings | -118.52M |
| Total Assets | 17.95M |
| Working Capital | 9.09M |
Cash Flow
In the last 12 months, operating cash flow was -$28.71M and capital expenditures -$88.00K, giving a free cash flow of -$28.79M.
| Operating Cash Flow | -28.71M |
| Capital Expenditures | -88.00K |
| Free Cash Flow | -28.79M |
| FCF Per Share | -22.8 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
FBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -105.95% |
| FCF Yield | -83.72% |
Analyst Forecast
The average price target for FBRX is $68.75, which is 192.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $68.75 |
| Price Target Difference | 192.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 28, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 28, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -15.05 |
| Piotroski F-Score | 2 |